Original articleSerlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Key words
Abbreviations used
Cited by (0)
Drs Yosipovitch and Ständer are cofirst authors.
Funding sources: Supported by Menlo Therapeutics Inc. Medical writing and editorial assistance were provided by ApotheCom (New York, NY) and funded by Menlo Therapeutics Inc.
Disclosure: Dr Yosipovitch has received grant/research support for his role as an investigator from Menlo Therapeutics Inc, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals, and Sun Pharma, and he has received honoraria for participation in advisory boards for Menlo Therapeutics Inc, Trevi, Novartis, Pfizer, OPKO Health Inc, Sanofi, Galderma, and Sienna. Dr Ständer has received grants/research support and honoraria for her role as an investigator and consultant from Menlo Therapeutics Inc; she has received honoraria for participation in advisory boards for Menlo Therapeutics Inc and has received patient fees from Menlo Therapeutics Inc. Dr Kerby has received personal fees from Velocity Pharmaceutical Development and is a shareholder and consultant to Menlo Therapeutics Inc. Dr Larrick is a cofounder of and owns stock in Menlo Therapeutics Inc. Drs Perlman and Schnipper are employees of Velocity Pharmaceutical Development, and they have received stock from Menlo Therapeutics Inc for their roles as advisors and consultants. Dr Zhang has received personal fees from Velocity Pharmaceutical Development; he is a shareholder and employee of Menlo Therapeutics Inc, and he reports patents issued to Menlo Therapeutics Inc. Dr Luger has received grant/research support for his role as an investigator from AbbVie, Celgene, Eli Lily, Janssen-Cilag, Mylan/Meda Pharmaceuticals, MSD, Novartis, and Pfizer, and he has received honoraria for participation in advisory boards for AbbVie, Celgene, CERIES, Eli Lilly, Galderma, Janssen-Cilag, La Roche Posay, Mylan/Meda, Novartis, and Pfizer and honoraria for his role as a speaker for AbbVie, Celgene, Galderma, Janssen-Cilag, La Roche Posay, Mylan/Meda, MSD, Novartis, and Pfizer. Dr Steinhoff has received honoraria for his role as a speaker from Menlo Therapeutics Inc, Galderma, and Eli Lily; for serving as a consultant for Menlo Therapeutics Inc; and for participating in advisory boards for Menlo Therapeutics Inc, Galderma, and Pierre Fabre Laboratories. Dr Tang has no conflicts of interest to disclose.
This work was submitted to and presented in part at the 26th European Academy of Dermatology and Venereology Congress, September 13-17, 2017, in Geneva, Switzerland, and presented at the Ninth World Congress on Itch, October 15-17, 2017, in Wroclaw, Poland.